Studies of PPLO infection. V. Inhibition of lymphocyte mitosis and antibody formation by mycoplasmal extracts

Subversion of the Immune Response by Human Pathogenic Mycoplasmas

Mycoplasmas are a large group of prokaryotes which is believed to be originated from Gram-positive bacteria via degenerative evolution, and mainly capable of causing a wide range of human and animal infections. Although innate immunity and adaptive immunity play crucial roles in preventing mycoplasma infection, immune response that develops after infection fails to completely eliminate this bacterium under certain circumstances. Thus, it is reasonable to speculate that mycoplasmas employ some mechanisms to deal with coercion of host defense system. In this review, we will highlight and provide a comprehensive overview of immune evasion strategies that have emerged in mycoplasma infection, which can be divided into four aspects: (i) Molecular mimicry and antigenic variation on the surface of the bacteria to evade the immune surveillance; (ii) Overcoming the immune effector molecules assaults: Induction of detoxified enzymes to degradation of reactive oxygen species; Expression of nucleases to degrade the neutrophil extracellular traps to avoid killing by Neutrophil; Capture and cleavage of immunoglobulins to evade humoral immune response; (iii) Persistent survival: Invading into the host cell to escape the immune damage; Formation of a biofilm to establish a persistent infection; (iv) Modulation of the immune system to down-regulate the intensity of immune response. All of these features increase the probability of mycoplasma survival in the host and lead to a persistent, chronic infections. A profound understanding on the mycoplasma to subvert the immune system will help us to better understand why mycoplasma is so difficult to eradicate and ultimately provide new insights on the development of therapeutic regimens against this bacterium in future.

Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis

BACKGROUND

The arginine-degrading enzyme, arginine deiminase conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw), reduces extracellular arginine, has minimal toxicity, decreases tumor burden and improves liver function in patients with chronic hepatitis C virus infection (HCV) and inoperable hepatocellular carcinoma (HCC). Reduced extracellular arginine inhibits viral replication through unknown mechanisms. It is hypothesized that ADI-SS PEG 20,000 mw reduces HCV viral titers through nitric oxide (NO)-dependent effects.

METHODS

The effects of ADI-SS PEG 20,000 mw (dose, 160 IU/m2; three cycles of four once-weekly i.m. injections) on HCV titers, serum NO and plasma arginine, were evaluated using archived plasma from patients with HCC and HCV and in vitro cell model measurements of HCV replication.

RESULTS

ADI-SS PEG 20,000 mw selectively inhibited HCV replication in vitro (IC50 = 0.027 IU/mL). Fifteen HCC/HCV patients completed treatment. The HCV titers were reduced by up to 99% in five out of 10 (50%) HCV-serotype 1b patients (P = 0.0093). These patients also experienced significant improvements in liver function (P = 0.0091). There were concomitant reductions of plasma arginine and serum NO levels. The HCV titer was not reduced in HCV-type 2c patients.

CONCLUSION

Reduction of extracellular arginine by ADI-SS PEG 20,000 mw in HCC patients reduces HCV viral titers and improves liver function, possibly through suppression of NO.

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

PURPOSE

Recently, we reported that a large number of human hepatocellular cancer (HCC) cell lines were auxotrophic for arginine. Here we report the results obtained with the amino acid-degrading enzyme arginine deiminase (ADI) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) as a means of lowering plasma arginine to treat HCC. The study was a cohort dose-escalation phase I/II study.

PATIENTS AND METHODS

Pharmacodynamic studies indicated an ADI-SS PEG 20,000 mw dose level of 160 U/m(2) was sufficient to lower plasma arginine from a resting level of approximately 130 micromol/L to below the level of detection (< 2 micromol/L) for more than 7 days, a dose later defined as the optimal biologic dose. All patients were to receive three cycles at the optimum biologic dose.

RESULTS

This therapy was well tolerated, even in patients who had no detectable plasma arginine for 3 continuous months of therapy. Of the 19 patients enrolled, two had a complete response, seven had a partial response, seven had stable disease, and three had progressive disease. The median survival for the 19 patients enrolled on this study was 410 days, with four patients still alive at present (> 680 days).

CONCLUSION

Elimination of all detectable plasma arginine in patients with HCC was well tolerated and seemed to be effective in the treatment of some patients with HCC. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with HCC as well as other human tumors auxotrophic for arginine is warranted.

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation

BACKGROUND

Argininosuccinate synthetase (ASS) was the first of two enzymes to convert citrulline to arginine. This pathway allowed cells to synthesize arginine from citrulline, making this amino acid nonessential for the growth of most mammalian cells. Previous studies demonstrated that several human tumor cell lines were auxotrophic for arginine due to an inability to express ASS. Selective elimination of arginine from the circulation of animals with these tumors is a potentially effective anticancer treatment. The purpose of these experiments was to determine the frequency of ASS deficiency and arginine auxotrophy in a variety of human malignant tumors.

METHODS

The authors analyzed the expression of ASS by immunohistochemistry with a monoclonal antibody in a variety of human tumor biopsies. They found that the incidence of ASS deficiency varied greatly with the tumor type and tissue of origin.

RESULTS

Melanoma, hepatocellular carcinoma, and prostate carcinoma were most frequently deficient in ASS. Some human cancers were almost always positive for ASS (e.g., lung and colon carcinomas). However, other human cancers, including sarcomas, invasive breast carcinoma, and renal cell carcinoma, also were sometimes ASS deficient.

CONCLUSIONS

These data indicated that immunohistochemical detection of ASS may prove an effective means for determining ASS deficiency in malignant human tumors and for identifying patients most likely to respond to arginine deprivation therapy. Based on these results, human clinical trials using arginine-degrading enzyme therapy to treat patients with advanced melanoma or hepatocellular carcinoma have been initiated.

Detection of mycoplasma contamination through modulation (stimulation or inhibition) of thymidine incorporation by unstimulated mouse spleen cells

In the present report we describe a rapid and sensitive assay for mycoplasma detection in cell cultures. The assay is based on the ability of contaminated culture supernatants to modulate [3H]TdR incorporation by unstimulated mouse splenocytes. Several mycoplasma species (Mycoplasma orale, culturable and non-culturable strains of Mycoplasma hyorhinis) inhibited [3H]TdR incorporation and permitted the detection of some contaminated cell cultures that would otherwise have escaped detection in assays measuring [3H]TdR incorporation by mitogen-stimulated splenocytes. On the other hand, several other mycoplasma species (Mycoplasma arginini, Mycoplasma hominis) strongly enhanced [3H]TdR incorporation by unstimulated splenocytes. This enhancement was optimally detectable on day 2 after initiation of the cultures. The sensitivity of the assay was determined for a mycoplasma species (culturable M. hyorhinis) that inhibited as well as for one (M. arginini) that enhanced [3H]TdR incorporation. In both cases, the sensitivity was such that 1-3 x 10(2) mycoplasma colony-forming units (CFU) could be detected.

Inhibitory effect of mycoplasma-released arginase. Activity in mixed-lymphocyte and tumour cell cultures

Non-fermenting mycoplasma species deplete culture media for arginine through arginase activity linked to their arginine deiminase pathway, resulting in proliferation arrest and cell death in mycoplasma-contaminated cell cultures. The presence of only 2-3 Mycoplasma (M.) arginini-contaminated T cells in a one-way allogeneic mixed-lymphocyte culture (MLC) significantly inhibits development of cytotoxic T-cell activity. Likewise, strong degrees of inhibition are observed after addition of nanogram doses of M. arginini extracts (MAE) to MLC or cell proliferation cultures. M. arginini-induced cell inhibition can be reversed by addition of excess arginine to the culture medium. Antisera raised against non-fermenting, but not against fermenting, mycoplasma species block the inhibitory effect of MAE. SDS-PAGE separation of MAE disclosed a broad band at 60 kDa which contained arginase activity when assayed in MLC and cell proliferation culture. SDS-PAGE followed by western blotting and reaction with antisera raised against non-fermenting mycoplasma species demonstrated a band at 43 kDa common for these micro-organisms.

The regulation of murine B cell differentiation. I. Nonspecific suppression caused by Mycoplasma arginini

During the screening of suppressor T cell (Ts) hybridomas for antigen-nonspecific suppressive activity, we isolated a strain of Mycoplasma arginini which inhibits B cell antibody production in vitro. The addition of mycoplasma-containing Ts hybridoma culture supernatant to splenic B cells responding to sheep red blood cells (SRBC) and T cell-replacing factor or to trinitrophenyl-lipopolysaccharide (TNP-LPS) suppressed the production of anti-SRBC and anti-TNP plaque-forming cells in a dose-dependent and antigen-nonspecific manner. Inhibition occurred due to the noncytotoxic mycoplasmal infection of B cells in culture and required the physical presence of microorganisms. Cell cycle analysis of acridine orange-stained B cells indicated that mycoplasmal infection did not block cell cycle entry and progression of antigen-activated cells. In addition to a suppressive activity, this strain of mycoplasma was selectively mitogenic for B cells. Furthermore, the mycoplasma failed to stimulate or inhibit T cell proliferation. The suppressive and mitogenic activities were selectively absorbed by mitogen-activated B cells but not T cells. These results indicate that this strain of M. arginini mimics the suppressive activity of an antigen-nonspecific Ts factor selective for B cell antibody production.

Suppression of monocyte functions by human cytomegalovirus

The role of the monocyte in human cytomegalovirus (HCMV)-induced immunosuppression was examined by assessing the ability of the virus to directly suppress various monocyte accessory cell functions. Both patient-derived and laboratory-adapted strains of HCMV were capable of impairing antigen-presenting functions of purified human monocytes. In seven of 12 virus-infected samples, there was a significant decrease (P less than 0.05) in the ability of HCMV-infected monocytes to present tetanus toxoid to autologous lymphocytes compared with mock-infected controls; similar results were obtained with Candida albicans and mumps. In contrast, the response to PHA was impaired in only one of eight HCMV-infected samples. The increased expression of MHC class II Ia antigens (HLA-DQ and HLA-DR) by monocytes after stimulation by interferon-gamma was impaired in approximately one-third of the 43 virus-infected samples tested. Interleukin-1 (IL-1) production after incubation with the stimulating antigens, however, was unaffected. Attempts to augment immuno-suppression by co-stimulation of monocytes with lipopolysaccharide (LPS), heat-killed Escherichia coli or Listeria monocytogenes were not successful; however, dramatically increased levels of immunosuppression was obtained with HCMV preparations containing mycoplasma. Thus, although HCMV is capable of directly perturbing monocyte accessory cell functions, the variability and partial suppression observed suggests that infection of monocytes by HCMV alone is not sufficient to produce the levels of immune hyporesponsiveness observed in HCMV-infected patients.

Inhibition of [3H]thymidine incorporation by Mycoplasma arginini-infected cells due to enzymatic cleavage of the nucleoside

Culture supernatants contaminated by Mycoplasma arginini inhibit the incorporation of [3H]thymidine ([3H]dThd) by cytotoxic T lymphocyte cell lines. This study presents evidence that the inhibition of uptake of the nucleoside is due to the rapid cleavage of the exogenous [3H]dThd into thymine. Uridine and cytidine as well as dThd are degraded by the mycoplasma-contaminated supernatants, while no cleavage was observed with uninfected supernatants. Cells contaminated by mycoplasma apparently release a pyrimidine-specific nucleosidase, possibly a dThd phosphorylase, which is responsible for the inhibition.

A sensitive and quantitative microassay for the detection of mycoplasma contamination: inhibition of IL-2 dependent cell line proliferation

A simple, rapid and sensitive microassay for mycoplasma detection in cell culture is reported. The assay is based on the fact that culture supernatants from contaminated cells inhibit [3H]thymidine incorporation by an IL-2 dependent mouse cytotoxic T cell line (CTLL). The mechanism of inhibition is related to the production by several mycoplasma strains of a pyrimidine-specific nucleoside phosphorylase which can degrade the radiolabelled thymidine used for the measurement of DNA synthesis. These strains were the commonest contaminants in cultures of 24 cell lines from 5 different sources. To establish the sensitivity of the test to detect mycoplasmas we have also used the inhibition assay to monitor the clearance of mycoplasma from 2 contaminated cell lines.

In vitro inhibition of allogeneic CTL generation and interferon gamma production by the cells of a chemically induced fibrosarcoma

We have previously shown that a highly tumorigeneic 3-methylcholanthrene transformed clone (MCA-C3H CL 15) of C3H10T1/2 fibroblasts and a normal nontransformed clone (C3H10 1/2 CL 8) from the same parental stock fail to stimulate the generation of syngeneic cytolytic effector cells. In attempting to further dissect and understand the immune response to these cells, we have extended our studies to examine their ability to stimulate the in vitro generation of allogeneic cytolytic effector cells. This model is unique in that studies of immune responses to tumor cells rarely have or utilize appropriate normal cell counterparts. The normal fibroblasts stimulated both the generation of allogeneic cytolytic T lymphocytes (CTL) and the production of immune interferon (IFN-gamma), whereas the tumor fibroblasts did not. The normal fibroblasts were negative for mycoplasma, indicating that these organisms did not account for the observed IFN-gamma induction. When added as third-party cells to cultures containing allogeneic responders and normal fibroblast stimulators, the tumor fibroblasts inhibited the generation of CTL as well as the production of IFN-gamma. The absence of IFN-gamma was not the result of the tumor fibroblasts absorbing or inactivating IFN-gamma, since culturing the tumor cells in IFN-gamma of predetermined activity did not appreciably alter that activity.

The immune response to a chemically induced fibrosarcoma: a comparison of cytolytic T lymphocyte stimulation by transformed and non-transformed fibroblasts

A clone of C3H10T 1/2 fibroblasts transformed in vitro with the carcinogen 3-methylcholanthrene readily produced tumors when as few as 103 cells were injected into immunocompetent adult syngeneic mice. A non-transformed clone of the same parentage did not produce tumors. Because the cell-mediated immune response has an important role in inhibiting the growth of tumors, we have compared the ability of both these transformed and non-transformed fibroblasts to stimulate and to act as targets in cell-mediated cytotoxicity (CMC) assays. This model is unique in that studies of the immune response to tumors rarely have or utilize appropriate normal controls. When both types of irradiated fibroblasts were used as stimulators in vitro, neither syngeneic nor allogeneic effector spleen cells capable of efficiently lysing the tumor fibroblasts were generated. In contrast, the normal fibroblasts could both stimulate and be lysed by allogeneic cytolytic T cells (CTL). However, the tumor fibroblasts could be lysed by allogeneic effector spleen cells that had been sensitized to C3H/He spleen cells. These results suggest that the expression of alloantigenic determinants necessary for stimulating a CMC response may vary substantially among ‘normal’ cell types. They further indicate that the tumor cells are not resistant to lysis by appropriately stimulated effector cells. Thus, they must express antigenic determinants necessary for immune lysis and they do not inhibit the functional expression of cytolytic cells once generated. Consequently, tumor growth in vivo may be dependent, in part, upon a failure of the syngeneic host's immunocompetent cells to respond appropriately to the tumor cells. Additional data are provided which suggest that this failure is attributable in large part to immunosuppressive properties of the tumor cells.

Behavior of Mycoplasma hominis in a human diploid cell culture system

The behavior of Mycoplasma hominis in normal human embryonic lung fibroblast (HAIN-55) cell cultures was investigated. Multiplication patterns of cell-associated mycoplasmas and of extracellular mycoplasmas in the HAIN-55 cultures depended upon the size of the inoculum. This relationship did not vary with the number of days the cells had been cultured, nor with the number of HAIN-55 cell passages. The maximum mycoplasmal growth was obtained with inoculum sizes of 10(5) to 10(6) colony-forming units (CFU)/ml. The recovery of mycoplasmas decreased rapidly with inoculum size beyond 10(7) CFU/ml, and growth of the HAIN-55 cells was inhibited. Growth of the cells was also inhibited by the addition of the cytoplasmic fraction of Mycoplasma hominis.

High nonspecific reactivity of normal lymphocytes against mycoplasma-infected target cells in cytotoxicity assays

Several rat tumor cell cultures were deliberately infected with three species of mycoplasma commonly found as contaminants of cell lines grown in vitro, and the effect of mycoplasma infection on the results of cytotoxicity assays was examined. Lymph node cells and spleen cells from normal animals showed an apparently high spontaneous cytotoxic activity against tumor cells infected with either M. arginini or M. hyorhinis, but the reactivity against cells infected with M. orale was not significantly higher than that against uninfected cells. The high reactivity towards tumor cells infected with M. arginini and M. hyorhinis bore a close resemblence to natural cell-mediated immunity in that spleen cells were much more reactive than lymph node cells, spleen cells from nude mice were as effective as spleen cells from normal mice, and the reaction crossed both strain and species barriers. However, closer examination revealed that the cytotoxic effects were directly caused by depletion of arginine or other essential nutrients from the medium. These findings imply that a cautious approach should be taken when interpreting certain aspects of spontaneous cell-mediated cytotoxicity, and that the greatest care be taken to ensure that the cells used as targets in any cytotoxicity test are mycoplasma-free.

Differential arginine dependence and the selective cytotoxic effects of activated macrophages for malignant cells in vitro

Normal and neoplastic cells from 4 species (man, rat, mouse and hamster) were examined for their dependence on exogenous L-arginine in tissue culture. The malignant cells required a higher concentration of L-arginine in the medium than their normal counterparts (with similar doubling times) to maintain optimal proliferation. Complete arginine deprivation resulted in equal growth inhibition of normal and malignant cells, but more rapid cytolysis of the malignant cell. Deprivation of L-arginine, followed 24 h later by rescue with L-arginine, allowed normal cells to proliferate, but the reproductive capacity of the malignant cells was irreversibly impaired. Since the cytotoxic activity of LPS-activated macrophages was associated with the release of arginase and was abrogated by excess L-arginine, it is suggested that the biological basis for the selective effects of such macrophages may reside in the L-arginine dependence of the target cells.

Mycoplasma-dependent activation of normal lymphocytes: induction of a lymphocyte-mediated cytotoxicity for allogeneic and syngeneic mouse target cells

Mycoplasma arthritidis, M. hominis, and M. arginini were tested for their ability to induce a cytotoxic response from normal CBA mouse lymphocytes against 51Cr-labeled allogeneic target cells. In most cases, the mycoplasmas alone were not toxic for the target cells. Furthermore, the mycoplasmas did not result in decreased lymphocyte viability but, in fact, contributed to enhanced lymphocyte survival. In the absence of normal CBA lymphocytes, mycoplasmas alone did not induce a significant amount of cell damage in either the allogeneic or the syngeneic target cells. Strains of M. arthritidis and M. hominis, when added to the lymphocyte-target cell mixtures, induced statistically significant increases in 51Cr release from both target cell types at each assay period after 6 h. The release of 51Cr was taken as a measure of cell death. M. arginini induced only low levels of cytotoxicity or none at all. Both arthritogenic and non-arthritogenic strains of M. arthritidis induced the cytotoxic response. The degree of cytotoxicity produced was directly related to the size of the initial inoculum. The presence or absence of serum in the culture medium did not contribute significantly to the cytotoxicity response.

Mycoplasma-dependent activation of normal lymphocytes: mitogenic potential of mycoplasmas for mouse lymphocytes

Nonviable preparations of a wide variety of glucose-utilizing mycoplasma species, including Acholeplasma laidlawii and Spiroplasma citri, were found to be mitogenic for mouse lymphocytes. Particularly strong reactions were obtained with Mycoplasma synoviae, M. gallisepticum, M. pneumoniae, S. citri, and a strain of M. fermentans that was previously isolated from a leukemic patient. Nonviable preparations of arginine-utilizing mycoplasmas inhibited the uptake of [3H]thymidine by lymphocytes, but this effect could be reversed by heat treatment or arginine supplementation, and a stimulatory effect was then observed. Viable M. arthritidis was also found to have a mitogenic effect, as detected by an increased uptake of [3H]thymidine by normal lymphocytes and by autoradiographic techniques in which an increase in the numbers of transformed cells was seen. These observations provide the potential for enhanced immunological responsiveness or lymphokine-mediated inflammation in mycoplasma-infected hosts.

In vitro inhibition of human peripheral blood lymphocyte transformation by an extract of Pseudomonas putida

An extract prepared from a psychrophilic strain of Pseudomonas putida was found to cause a dose-dependent inhibition of [H3]TdR incorporation into human peripheral blood lymphocytes stimulated with PHA, ConA, PWM, or in a mixed lymphocyte reaction. The inhibition was found not to be the result of cytotoxicity, culture medium depletion of a component necessary for lymphocyte transformation, or interference with label uptake by blast lymphocytes. The extract was most effective when added prior to 48 h of mitogen stimulation. The inhibitory material was photeolytic enzyme degradable, heat-stable and non-dialyzable.

Arthritis of mice induced by Mycoplasma arthritidis. Humoral antibody and lymphocyte responses of CBA mice

Peak arthritis occurred 7 days after intravenous injection of CBA mice with Mycoplasma arthritidis and persisted in some animals for 84 days. A marked leucocytosis was apparent for the first 21 days. Complement-fixing antibodies reached a peak 14 days after injection of the organisms and persisted at high levels for 84 days. Metabolic-inhibiting and mycoplasmacidal antibodies were present but at much lower titres.

Disparity in the production of lymphoblastogenesis inhibition factor by cultured human B and T lymphoid cell lines

A comparative study of inhibitory effects of cell-free supernatants from cultured human B and T lymphoid cell lines on lymphocyte blastogenesis indicated that the inhibitory effect of supernatant from B lymphoid cells on lymphocyte blastogenesis was significantly higher than that of supernatant from T lymphoid cells or from non-lymphoid neoplastic cells. The inhibitory effect of supernatant was reversible and dose-related. The inhibitory effect gradually diminished with time when the supernatant from B lymphoid cells was added to the culture, 1-3 days after the beginning of cultures. The supernatant of human B lymphoid cells was also found to be highly active in affecting the mouse thymus cell response. The biological nature of this inhibitory factor has not been defined. Both B lymphoid cell lines used in the present study contained Epstein-Barr virus (EBV) genomes while the T-cell line and the non-lymphoid neoplastic cell lines were free of EBV genomes. Sensitivity of the supernatant of B lymphoid cells to u.v. irradiation and heat suggests the possibility that the EBV genomes released into the culture medium may be responsible for inhibition of lymphocyte blastogenesis; resistance of this supernatant to DNase suggests that the EBV genomes may be double-stranded DNA.

A potent antimitogenic factor from group A streptococci

A cytoplasmic component from group A streptococci produced complete suppression of human lymphocyte transformation induced by phytohaemagglutinin or the mixed lymphocyte reaction in vitro. It also suppressed antibody-forming cells in mice against sheep erythrocytes. The active substance was eluted as second and third fractions form Sephadex G-200 chromatography of the 100,000 g supernatant of sonically ruptured group A streptococci. The antimitogenic activity was not susceptible to trypsin, pronase, RNase or DNase digestion, but the activity was completely lost when it was sequentially digested, first with RNase and DNase and then with pronase. The active substance was not antigenic nor heat-labile at 56 degrees. It may be a protein component of a nucleoprotein.

The immunosuppressive effect of mycoplasma infection. I. Effect on the humoral and cellular response

Mycoplasma-induced immunosuppression in rats was demonstrated with Mycoplasma arthritidis strain PN. Immunosuppression involving the humoral antibody response was complete or partial when mycoplasma was injected concurrently with the antigen. Mycoplasma did not interfere with the antibody response when injected after primary immunization.

Inhibition of blast transformation was shown to occur in lymphocytes derived from rats infected with the above mycoplasma. The inhibition was partial or complete depending on the interval between the infection and the time when the lymphocytes were taken from the animal, and blast transformation reverted to normal when the infection was over.

Although the question of mechanism remains open, it was concluded that immunosuppression might be the result of the effect of M. arthritidis on a particular population of cells.

Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy

A patient with chronic mucocutaneous candidiasis and cutaneous anergy has been studied and found to have a circulating plasma factor capable of quenching in vitro lymphocyte responses of leucocytes of clinically well donors to monilia and other specific mitogenic stimulants. After instituting systemic amphotericin B therapy, the patient exhibited rapid clearing of cutaneous and mucosal lesions and the plasma inhibitor was no longer demonstrable. Loss of the plasma inhibitor was followed by appearance of strong cutaneous hypersensitivity and in vitro leucocyte responses to Candida albicans and streptococcal products. These clinical immunologic studies have pointed meaning in relationship to current views regarding immunologic reconstitution vis-à-vis systemic antifungal therapy in treatment of chronic candidiasis.

Studies on the immunosuppressive properties of asparaginase

The effect of asparaginase on lymphocyte kinetics and on immunological competence of normal and adrenalectomized mice has been studied. Treatment of mice with this enzyme results in lymphocytopenia and atrophy of lymph nodes, thymus and spleen. The lymph node lymphocytes from asparaginase-treated mice do not migrate normally to lymphoid organs when injected intravenously into syngeneic recipients. Splenic lymphocytes from asparaginase-treated mice induce significantly less graft-versus-host reaction when injected into F₁ hybrids and incorporate significantly less thymidine into DNA when cultured in vitro with phytohaemagglutinin than do cells from normal mice. Skin graft rejection and the formation of antibody to sheep erythrocytes is significantly inhibited by administration of asparaginase. The immunosuppressive actions of asparaginase are manifested in adrenalectomized mice. Studies on the inhibition of phytohaemagglutinin-induced lymphocyte transformation by asparaginase suggest that asparagine depletion underlies the effect of asparaginase on lymphocytes.

Mycoplasmas and cell cultures

Images

L-glutaminase: suppression of lymphocyte blastogenic responses in vitro

Continuous exposure to 0.1 international unit or more of Escherichia coli L-glutaminase inhibited responses of human lymphocytes to phytohemagglutinin, streptolysin O, and allogeneic leukocytes. Inhibition was completety reversed by removing the enzyme from the culture or adding L-glutamine but not L-asparagine. Cytoxicity did not occur. L-Glutaminase should be immunosuppressive in vivo.

Cellular recognition by mouse lymphocytes in vitro. I. Definition of a new technique and results of stimulation by phytohemagglutinin and specific antigens

The media and culture conditions required for in vitro stimulation of mouse lymphoid cells are described. The medium was arginine-rich and contained heat-inactivated human serum. A component of the human sera necessary for stimulation of the cells was a natural mouse cell agglutinin, which affected both background stimulation and the degree of induced stimulation with phytohemagglutinin (PHA). Absorption of the agglutinin from the human serum rendered the medium incapable of sustaining DNA synthesis in the presence of PHA. The response to PHA of mouse spleen and thymus cells was age-dependent and, although this response was not present at birth, it rapidly rose to adult levels. Spleen cells from mice immunized with bacillus Calmette-Guérin (BCG) or sheep erythrocytes (SRBC) showed increased in vitro reactivity to added purified protein derivative (PPD) or SRBC stroma, dependent on the time of immunization. The dose response curve for the SRBC stroma stimulated, immune spleen cells is compatible with a theory of cell to cell interaction being necessary for an in vitro reaction to antigen. The possible role of the mouse cell agglutinin (AMLG) is discussed.